Novan (NOVN)
0.09
0.00 (0.00%)
Upcoming Events
Latest Headlines
New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies
February 25, 2024 2:00 PM - PR NewsWire
Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis
February 20, 2024 8:10 AM - Globe NewsWire
FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies
February 16, 2024 11:21 AM - PR NewsWire
Form S-8 POS NOVARTIS AG
February 15, 2024 4:16 PM - SEC Filing
Form SC 13G/A NOVARTIS AG Filed by: BlackRock Inc.
February 2, 2024 2:19 PM - SEC Filing
Form 6-K NOVARTIS AG For: Dec 31
January 31, 2024 7:45 AM - SEC Filing
Form 6-K NOVARTIS AG For: Dec 31
January 31, 2024 7:44 AM - SEC Filing
Form IRANNOTICE NOVARTIS AG
January 31, 2024 7:42 AM - SEC Filing
Form 20-F NOVARTIS AG For: Dec 31
January 31, 2024 7:40 AM - SEC Filing
Form 6-K NOVARTIS AG For: Jan 08
January 8, 2024 6:14 AM - SEC Filing
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
January 5, 2024 9:23 AM - Globe NewsWire
Full Article List